Agios Pharmaceuticals Inc (AGIO)

Form 4 - Statement of changes in beneficial ownership of securities

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with...

Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

Agios obtains exclusive global rights to novel, late-stage, next-generation, oral SYK inhibitor Agreement...

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

Results did not meet predefined threshold to support further development in LR-MDSTebapivat was well tolerated...

Agios, partenaire d’Avanzanite Bioscience, annonce l’autorisation de mise sur le marché de PYRUKYND® (mitapivat) dans l’Union européenne pour les adultes atteints de thalassémie

Avanzanite commercialisera et distribuera PYRUKYND en Europe dans le cadre de son accord exclusif avec Agios...

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios...

Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-depen...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease

sNDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated approval...

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

Detailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Agios Reports First Quarter 2026 Financial Results and Provides Business Update

Mitapivat (PYRUKYND® and AQVESME™) generated worldwide net revenues of $20.7 million in the first quarter of...